← Back to Screener
NovaBay Pharmaceuticals, Inc. (NBY)
Price$1.57
Favorite Metrics
Price vs S&P 500 (26W)-77.82%
Price vs S&P 500 (4W)16.83%
Market Capitalization$51.92M
Indicated Dividend Yield (Annual)0.00%
All Metrics
P/CF (Annual)19.21x
Book Value / Share (Quarterly)$1.36
P/TBV (Annual)0.40x
Revenue Growth (3Y)5.12%
Cash Flow / Share (Quarterly)$0.11
Price vs S&P 500 (YTD)-97.08%
Gross Margin (TTM)54.56%
Net Profit Margin (TTM)-88.52%
EPS (TTM)$-4.09
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$-4.09
Revenue Growth (5Y)8.19%
EPS (Annual)$-2.13
Dividend / Share (Annual)$0.37
ROI (Annual)-216.58%
Gross Margin (Annual)66.26%
Net Profit Margin (5Y Avg)-78.66%
Cash / Share (Quarterly)$0.32
Revenue Growth QoQ (YoY)-78.66%
ROA (Last FY)-211.01%
Revenue Growth TTM (YoY)-74.73%
EBITD / Share (TTM)$-4.01
ROE (5Y Avg)-306.84%
Operating Margin (TTM)-89.93%
Cash Flow / Share (Annual)$0.11
P/B Ratio31.77x
P/B Ratio (Quarterly)4.70x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)15.56x
Net Interest Coverage (TTM)-399.56x
ROA (TTM)-460.21%
EV / EBITDA (TTM)49.47x
EPS Incl Extra (Annual)$-2.13
Current Ratio (Annual)7.60x
Quick Ratio (Quarterly)7.33x
3-Month Avg Trading Volume0.51M
52-Week Price Return-43.93%
EV / Free Cash Flow (Annual)16.29x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$10.33
P/S Ratio (Annual)5.31x
Asset Turnover (Annual)2.86x
52-Week High$99.75
Operating Margin (5Y Avg)-76.31%
EPS Excl Extra (Annual)$-2.13
CapEx CAGR (5Y)-21.40%
Tangible BV CAGR (5Y)25.03%
26-Week Price Return-73.83%
Quick Ratio (Annual)7.33x
13-Week Price Return-97.67%
Total Debt / Equity (Annual)0.34x
Current Ratio (Quarterly)7.60x
Enterprise Value$44.028
Revenue / Share Growth (5Y)-23.01%
Asset Turnover (TTM)0.82x
Book Value / Share Growth (5Y)38.59%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.81x
Pretax Margin (Annual)-73.71%
Cash / Share (Annual)$0.32
3-Month Return Std Dev216.42%
Gross Margin (5Y Avg)60.92%
Net Income / Employee (TTM)$-2
ROE (Last FY)-290.89%
Net Interest Coverage (Annual)-152.45x
EPS Basic Excl Extra (Annual)$-2.13
P/FCF (TTM)5.58x
Receivables Turnover (TTM)5.28x
EV / Free Cash Flow (TTM)16.29x
Total Debt / Equity (Quarterly)0.09x
EPS Incl Extra (TTM)$-4.09
Receivables Turnover (Annual)17.04x
ROI (TTM)-104.74%
P/S Ratio (TTM)18.35x
Pretax Margin (5Y Avg)-78.61%
Revenue / Share (Annual)$2.88
Tangible BV / Share (Annual)$51.64
Price vs S&P 500 (52W)-73.76%
Year-to-Date Return-94.43%
5-Day Price Return-0.63%
EPS Normalized (Annual)$-2.13
ROA (5Y Avg)-95.83%
Net Profit Margin (Annual)-73.85%
Month-to-Date Return5.37%
Cash Flow / Share (TTM)$-5.24
EBITD / Share (Annual)$-2.11
Operating Margin (Annual)-59.83%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)19.21x
ROI (5Y Avg)-146.64%
LT Debt / Equity (Quarterly)1.65x
EPS Basic Excl Extra (TTM)$-4.09
P/TBV (Quarterly)0.40x
P/B Ratio (Annual)0.40x
Inventory Turnover (TTM)1.81x
Pretax Margin (TTM)-93.85%
Book Value / Share (Annual)$51.64
Price vs S&P 500 (13W)-98.35%
Beta0.18x
P/FCF (Annual)19.21x
Revenue / Share (TTM)$2.41
ROE (TTM)-109.37%
52-Week Low$1.11
Analyst Recommendations
Jun 2025
Jul 2025
Aug 2025
Oct 2025
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NBYNovaBay Pharmaceuticals, Inc. | 18.35x | -74.73% | 54.56% | — | $1.57 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
NovaBay Pharmaceuticals develops and commercializes clinically-proven eyecare, wound care, and skin care products. Its flagship product, Avenova Antimicrobial Lid and Lash Solution, is marketed directly to consumers online and prescribed by eyecare professionals for blepharitis and dry-eye disease. The product features broad-spectrum antimicrobial properties to remove microorganisms and debris from the eye area.